Glenmark Pharmaceuticals Q1 FY27 Revenue Surges 23.1% to ₹40,185 Million
Glenmark Pharmaceuticals reported Q1 FY27 consolidated revenue of ₹40,185 million, up 23.1% YoY. India grew 15.5%, North America 41.1%, EU 11.9%, and Emerging Markets 27.7%. EBITDA stood at ₹8,048 million, and PAT at ₹4,828 million. RYALTRIS® commercialized in 57 markets, with US launch initiated. Oncology pipeline progressing.
Significant revenue growth, improved profitability, and positive developments in the product pipeline and clinical trials are likely to have a substantial positive impact on investor sentiment and the company's market position.
The company reported strong year-on-year revenue growth across all key markets, improved profitability metrics, and positive updates on its innovative product pipeline and clinical trials.
Glenmark Pharmaceuticals Limited announced its financial results for the first quarter of FY27 (ended June 30, 2026), reporting a consolidated revenue of ₹40,185 million, a significant year-on-year growth of 23.1%.
The company witnessed broad-based growth across its key markets. The India business grew by 15.5%, driven by new launches in Respiratory and Oncology, and continued strength in the Consumer Care franchise. North America showed robust underlying growth of 41.1% (including deferred out-licensing income), with 9 new products launched, including the first generic approval of FloVent® HFA 44 mcg and the initiation of RYALTRIS® commercialization. The EU business expanded by 11.9%, with strong contributions from the branded portfolio in Respiratory and Dermatology, including the launch of WINLEVI® in the UK and select EU markets. Emerging Markets demonstrated strong momentum with 27.7% growth, particularly in Russia, LATAM, and MEA.
Profitability metrics include consolidated R&D expenses of ₹2,494 million, EBITDA of ₹8,048 million (20.03% margin), and Profit After Tax (PAT) of ₹4,828 million (11.8% margin).
In its global innovative portfolio, RYALTRIS® is now commercialized in 57 markets, with recent launches in China, Thailand, and initiation in the USA. WINLEVI® has seen continued uptake in the UK and expansion into several EU markets. The company also provided updates on its oncology pipeline, including QiNHAYO™ (ENVAFOLIMAB) with marketing authorization applications filed in 24 countries, and TRASTUZUMAB REZETECAN, with first wave of MA applications expected in Q2 FY27. IGI provided key updates on ISB 2001 (ABBV-2001), with promising safety and efficacy data from Phase 1 trials, and initiation of a combination study. ISB 2301, a first-in-class multispecific immune cell activator targeting solid tumors, is expected to have an IND submission later this year (CY26).
Glenmark Pharmaceuticals Limited has started FY27 with strong execution and resilience, reinforcing its focus on strengthening core businesses while expanding differentiated specialty and innovation-led platforms for disciplined, sustainable, and profitable growth.
What to do with a filing like this
Glenmark Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Glenmark Pharmaceuticals Limited. Read the original for the full detail.